Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUI5PA)

Drug Name

Brostallicin Drug Info

Synonyms

Brostallicin; UNII-RPC6R41K4I; 203258-60-0; RPC6R41K4I; PNU-166196A; Brostallicin [INN]; AC1OCFEA; SCHEMBL3678233; CHEMBL1189025; DTXSID70174222; ZINC3979512; Z-3228; 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]

Cross-matching ID

PubChem CID: 6918408
CAS Number: CAS 203258-60-0
TTD Drug ID: DMUI5PA

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human Deoxyribonucleic acid minor groove (hDNA min)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lurbinectedin	DMEFRTZ	Small-cell lung cancer	2C25.Y	Approved	[3]
Di-imidazole lexitropsin	DME4NH1	Discovery agent	N.A.	Investigative	[4]
Duocarmycin	DM0CQIP	Discovery agent	N.A.	Investigative	[5]
Netropsin	DMOW2QS	Discovery agent	N.A.	Investigative	[6]
Distamycin A	DMPVNDK	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid minor groove (hDNA min)	TTOVXHF	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00633165) Brostallicin Clinical Trial for Myxoid Liposarcoma. U.S. National Institutes of Health.
2	Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4	Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46.
5	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
6	Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7.
7	Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14.